Tudor Oprea, MD, PhD

CEO at Expert Systems Inc

Professor Emeritus of Medicine at The UNM School of Medicine

Dr. Tudor Oprea is a seasoned expert in machine learning, computational biology, and drug discovery, with over 30 years of experience. Currently, as CEO and Chief Scientific Officer at Expert Systems Inc., he drives innovations in drug target identification and machine learning applications in healthcare.

A co-inventor of G1 (LNS8801), a selective GPER agonist with orphan drug designation, Dr. Oprea is also known for developing cheminformatics tools and platforms like Pharos and DrugCentral. His work focuses on drug repositioning, virtual screening, and the exploration of drug-like properties.

Dr. Oprea has held senior roles in academia and industry, including Vice President of Translational Informatics at Roivant Discovery and Associate Director at AstraZeneca, where he led award-winning projects. As a Professor Emeritus at the University of New Mexico, he helped pioneer translational informatics, combining biomedical research with advanced data science.

Specialties: Machine Learning, Drug Discovery, Target Repositioning, Computational Chemistry, Bioinformatics.

Find his research here.

Author in
Tools & Methods

About one in three human proteins is understudied. Even when quantifying data is available from multiple sources, "dark" genes and proteins are simply not well characterized (Figure 1).

There may be multiple reasons why dark genes are ignored, although the literature isn't always in agreement with data availability.

Are you curious where dark gene hunting leads? There are a number of resources:

Tudor Oprea, MD, PhD

Recent articles from Tudor

Hunting Dark Genes For Druggable Targets